These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 8389668

  • 1. Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose.
    Rege SD, Hoh CK, Glaspy JA, Aberle DR, Dahlbom M, Razavi MK, Phelps ME, Hawkins RA.
    Cancer; 1993 Jul 01; 72(1):82-90. PubMed ID: 8389668
    [Abstract] [Full Text] [Related]

  • 2. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer?
    Aquino SL, Fischman AJ.
    Chest; 2004 Sep 01; 126(3):755-60. PubMed ID: 15364753
    [Abstract] [Full Text] [Related]

  • 3. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer.
    Sazon DA, Santiago SM, Soo Hoo GW, Khonsary A, Brown C, Mandelkern M, Blahd W, Williams AJ.
    Am J Respir Crit Care Med; 1996 Jan 01; 153(1):417-21. PubMed ID: 8542152
    [Abstract] [Full Text] [Related]

  • 4. Staging of recurrent and advanced lung cancer with 18F-FDG PET in a coincidence technique (hybrid PET).
    Schmid RA, Hautmann H, Poellinger B, Kellner W, Moisseev A, Brinkbaeumer K, Weiss M, Hahn K, Dresel S.
    Nucl Med Commun; 2003 Jan 01; 24(1):37-45. PubMed ID: 12501018
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A comparative study of 11C-choline PET and [18F]fluorodeoxyglucose PET in the evaluation of lung cancer.
    Khan N, Oriuchi N, Zhang H, Higuchi T, Tian M, Inoue T, Sato N, Endo K.
    Nucl Med Commun; 2003 Apr 01; 24(4):359-66. PubMed ID: 12673163
    [Abstract] [Full Text] [Related]

  • 7. Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose.
    Hoh CK, Hawkins RA, Glaspy JA, Dahlbom M, Tse NY, Hoffman EJ, Schiepers C, Choi Y, Rege S, Nitzsche E.
    J Comput Assist Tomogr; 1993 Apr 01; 17(4):582-9. PubMed ID: 8331230
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Whole-body [18F]FDG PET in the management of metastatic brain tumours.
    Kim DG, Kim CY, Paek SH, Lee DS, Chung JK, Jung HW, Cho BK.
    Acta Neurochir (Wien); 1998 Apr 01; 140(7):665-73; discussion 673-4. PubMed ID: 9781280
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Clinical significance of intrathoracic lesions detected by 18F-fluorodeoxyglucose positron emission tomography in the management of patients with head and neck cancer.
    Roh JL, Ryu CH, Kim JS, Lee JS, Choi SH, Nam SY, Kim SY.
    Oral Oncol; 2007 Sep 01; 43(8):757-63. PubMed ID: 17112773
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Comparison of FDG-PET findings of brain metastasis from non-small-cell lung cancer and small-cell lung cancer.
    Lee HY, Chung JK, Jeong JM, Lee DS, Kim DG, Jung HW, Lee MC.
    Ann Nucl Med; 2008 May 01; 22(4):281-6. PubMed ID: 18535878
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Characterization of chest masses by FDG positron emission tomography.
    Hübner KF, Buonocore E, Singh SK, Gould HR, Cotten DW.
    Clin Nucl Med; 1995 Apr 01; 20(4):293-8. PubMed ID: 7788982
    [Abstract] [Full Text] [Related]

  • 16. [18F] 3-deoxy-3'-fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-[18f]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions?
    Halter G, Buck AK, Schirrmeister H, Wurziger I, Liewald F, Glatting G, Neumaier B, Sunder-Plassmann L, Reske SN, Hetzel M.
    J Thorac Cardiovasc Surg; 2004 Apr 01; 127(4):1093-9. PubMed ID: 15052207
    [Abstract] [Full Text] [Related]

  • 17. Controlled prospective study of positron emission tomography using the glucose analogue [18f]fluorodeoxyglucose in the evaluation of pulmonary nodules.
    Präuer HW, Weber WA, Römer W, Treumann T, Ziegler SI, Schwaiger M.
    Br J Surg; 1998 Nov 01; 85(11):1506-11. PubMed ID: 9823912
    [Abstract] [Full Text] [Related]

  • 18. Thoracic FDG PET: state of the art.
    Erasmus JJ, McAdams HP, Patz EF, Goodman PC, Coleman RE.
    Radiographics; 1998 Nov 01; 18(1):5-20. PubMed ID: 9460106
    [Abstract] [Full Text] [Related]

  • 19. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
    Torizuka T, Nobezawa S, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, Takekuma M, Maeda M, Ouchi Y.
    Eur J Nucl Med Mol Imaging; 2002 Jun 01; 29(6):797-803. PubMed ID: 12029554
    [Abstract] [Full Text] [Related]

  • 20. Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients.
    Wu Y, Li P, Zhang H, Shi Y, Wu H, Zhang J, Qian Y, Li C, Yang J.
    Int J Cancer; 2013 Jan 15; 132(2):E37-47. PubMed ID: 22890912
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.